ÀڱñÙÁ¾ Ä¡·á ½ÃÀå : ¼¼°è »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø, À¯Çüº°, Ä¡·áº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°, °æÀﺰ(2020-2030³â)
Uterine Fibroids Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By End-User, By Region and Competition, 2020-2030F
»óǰÄÚµå : 1667942
¸®¼­Ä¡»ç : TechSci Research
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 186 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,165,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,535,000
PDF and Excel (Multi-User License) help
PDF ¹× Excel º¸°í¼­¸¦ ±â¾÷ÀÇ ÆÀÀ̳ª ±â°ü¿¡¼­ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,000 £Ü 10,960,000
PDF and Excel (Custom Research License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. 80½Ã°£ÀÇ ¾Ö³Î¸®½ºÆ® ŸÀÓÀÌ Æ÷ÇԵǾî ÀÖ°í Copy & Paste °¡´ÉÇÑ PPT ¹öÀüµµ Á¦°øµË´Ï´Ù. ªÀº Bespoke ¸®¼­Ä¡ ÇÁ·ÎÁ§Æ® ¼öÇà¿¡ ¸Â´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀڱñÙÁ¾ Ä¡·á ¼¼°è ½ÃÀåÀº 2024³â 47¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ù½À´Ï´Ù. 2030³â¿¡´Â 77¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 8.53%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº °¡Àӱ⠿©¼ºÀÇ ÀڱñÙÁ¾ À¯º´·ü Áõ°¡ÀÔ´Ï´Ù. ÀڱñÙÁ¾Àº Àڱÿ¡ ¹ß»ýÇÏ´Â ºñ¾Ï¼º Á¾¾çÀ¸·Î Àü ¼¼°è ¿©¼ºÀÇ »ó´ç¼ö°¡ ¾Î°í ÀÖÀ¸¸ç, ¿ù°æ°ú´Ù, °ñ¹ÝÅë, »ý½Ä ÇÕº´Áõ µîÀÇ Áõ»óÀ» À¯¹ßÇÏ´Â ÁúȯÀÔ´Ï´Ù. ÀڱñÙÁ¾°ú °ü·ÃµÈ °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ´õ ¸¹Àº ¿©¼ºµéÀÌ ÀÇ·áÀû °³ÀÔÀ» ¿äûÇϰí ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀǾàǰÀÇ ¹ßÀü, ÃÖ¼Òħ½À ¼ö¼úÀÇ Çõ½Å, ºñ¼ö¼úÀû Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¿ªÇÐÀÌ ÀçÆíµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í Ç¥Àû Ä¡·á·ÎÀÇ ÀüȯÀº ȯÀÚ °á°úÀÇ °³¼±À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2030³â
½ÃÀå ±Ô¸ð : 2024³â 47¾ï 4,000¸¸ ´Þ·¯
½ÃÀå ±Ô¸ð : 2030³â 77¾ï 6,000¸¸ ´Þ·¯
CAGR : 2025-2030³â 8.53%
±Þ¼ºÀå ºÎ¹® Àڱà ÀûÃâ¼ú
ÃÖ´ë ½ÃÀå ºÏ¹Ì

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

ÀڱñÙÁ¾ À¯º´·ü Áõ°¡

ÁÖ¿ä ½ÃÀå À̽´

ºñ¼ö¼úÀû Ä¡·á ¿É¼ÇÀÇ ÇѰè

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå °í°´ÀÇ ¼Ò¸®

Á¦5Àå ¼¼°èÀÇ ÀڱñÙÁ¾ Ä¡·á ½ÃÀå Àü¸Á

Á¦6Àå ºÏ¹ÌÀÇ ÀڱñÙÁ¾ Ä¡·á ½ÃÀå Àü¸Á

Á¦7Àå À¯·´ÀÇ ÀڱñÙÁ¾ Ä¡·á ½ÃÀå Àü¸Á

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀڱñÙÁ¾ Ä¡·á ½ÃÀå Àü¸Á

Á¦9Àå ³²¹ÌÀÇ ÀڱñÙÁ¾ Ä¡·á ½ÃÀå Àü¸Á

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀڱñÙÁ¾ Ä¡·á ½ÃÀå Àü¸Á

Á¦11Àå ½ÃÀå ¿ªÇÐ

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

Á¦13Àå PorterÀÇ Five Forces ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

Á¦15Àå Àü·«Àû Á¦¾È

Á¦16Àå ¸®¼­Ä¡»ç¿¡ ´ëÇØ & ¸éÃ¥»çÇ×

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global uterine fibroids treatment market was valued at USD 4.74 billion in 2024 and is projected to reach USD 7.76 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.53% during the forecast period. This growth is primarily driven by the increasing prevalence of uterine fibroids among women of reproductive age. Uterine fibroids, non-cancerous tumors that develop in the uterus, affect a significant proportion of women worldwide, leading to symptoms such as heavy menstrual bleeding, pelvic pain, and reproductive complications. Rising awareness of fibroid-related health issues is encouraging more women to seek medical interventions, thereby increasing the demand for effective treatment options. Advancements in pharmaceuticals, innovations in minimally invasive procedures, and a growing preference for non-surgical treatments are reshaping the market dynamics. Additionally, the shift toward personalized medicine and targeted therapies is driving improved patient outcomes.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.74 Billion
Market Size 2030USD 7.76 Billion
CAGR 2025-20308.53%
Fastest Growing SegmentHysterectomy
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Uterine Fibroids

The rising incidence of uterine fibroids is a key driver of market growth. Uterine fibroids, benign growths in the uterus, have become increasingly common, especially among women, impacting their quality of life and reproductive health. Factors such as delayed childbearing, changing lifestyles, and obesity are contributing to the rise in fibroid diagnoses. According to the Centers for Disease Control and Prevention (CDC) in 2021, 14.6% of women aged 18 and older in the United States have undergone a hysterectomy, a common surgical treatment for uterine fibroids. As more women experience symptoms such as heavy menstrual bleeding, pelvic pain, and fertility issues, the demand for medical interventions is increasing.

This growing patient population represents a substantial market opportunity for healthcare providers, pharmaceutical companies, and medical device manufacturers. In response, there has been a surge in research and development, leading to innovative treatments such as minimally invasive surgeries, pharmaceutical interventions, and novel therapies targeting the molecular mechanisms of fibroid growth.

Additionally, the rise in uterine fibroid awareness campaigns, improved access to healthcare, and enhanced patient education have made it easier for women to seek timely medical care, further driving the demand for uterine fibroid treatments. As the incidence of uterine fibroids continues to grow, there is a pressing need for innovative and patient-centric solutions.

Key Market Challenges

Limited Non-Surgical Treatment Options

A major challenge facing the global uterine fibroids treatment market is the limited availability of non-surgical alternatives. While surgical interventions have traditionally been the primary treatment option, non-surgical treatments are becoming increasingly important for women who wish to preserve fertility, reduce risks, and minimize recovery times.

Current pharmaceutical treatments, such as GnRH agonists and selective progesterone receptor modulators (SPRMs), help alleviate symptoms and reduce fibroid size. However, they often come with side effects, including hot flashes, bone density loss, and mood swings, and may not offer long-term solutions since fibroids tend to regrow after treatment discontinuation.

Minimally invasive non-surgical procedures like uterine artery embolization (UAE) and focused ultrasound surgery (FUS) have gained popularity. UAE blocks blood flow to the fibroids, causing them to shrink, while FUS uses high-intensity ultrasound waves to destroy them. Though these treatments are less invasive, they are not suitable for all patients. For example, UAE may not be ideal for women planning to conceive, and FUS has limitations regarding the size and location of fibroids it can treat. Moreover, access to these procedures can be limited by cost and availability, particularly in regions with constrained healthcare resources.

Key Market Players

Report Scope

The global uterine fibroids treatment market is segmented as follows:

By Type:

By Treatment:

By End-User:

By Region:

Competitive Landscape

The report includes detailed company profiles of major players in the global uterine fibroids treatment market.

Available Customizations

TechSci Research offers the following customizations to the global uterine fibroids treatment market report:

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Uterine Fibroids Treatment Market Outlook

6. North America Uterine Fibroids Treatment Market Outlook

7. Europe Uterine Fibroids Treatment Market Outlook

8. Asia-Pacific Uterine Fibroids Treatment Market Outlook

9. South America Uterine Fibroids Treatment Market Outlook

10. Middle East and Africa Uterine Fibroids Treatment Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Porters Five Forces Analysis

14. Competitive Landscape

15. Strategic Recommendations

16. About Us & Disclaimer

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â